Updates to the Alberta Drug Benefit List. Effective December 1, 2018
|
|
- Hannah Jefferson
- 5 years ago
- Views:
Transcription
1 Updates to the Alberta Drug Benefit List Effective December 1, 2018
2 Inquiries should be directed to: Pharmacy Services Alberta Blue Cross Street NW Edmonton AB T5J 3C5 Telephone Number: (780) (Edmonton) (403) (Calgary) (Toll Free) FAX Number: (780) (Toll Free) Website: Administered by Alberta Blue Cross on behalf of Alberta Health. The Drug Benefit List (DBL) is a list of drugs for which coverage may be provided to program participants. The DBL is not intended to be, and must not be used as a diagnostic or prescribing tool. Inclusion of a drug on the DBL does not mean or imply that the drug is fit or effective for any specific purpose. Prescribing professionals must always use their professional judgment and should refer to product monographs and any applicable practice guidelines when prescribing drugs. The product monograph contains information that may be required for the safe and effective use of the product. Copies of the Alberta Drug Benefit List are available from Pharmacy Services, Alberta Blue Cross at the address shown above. Binder and contents: ( G.S.T.) Contents only: ( G.S.T.) A cheque or money order must accompany the request for copies. ABC 40211/81160 (R2018/12)
3 UPDATES TO THE ALBERTA DRUG BENEFIT LIST Table of Contents Special Authorization... 1 New Product(s) Available by Special Authorization... 1 Additional Brand(s) and/or Strength(s) of Drug Product(s) Available by Special Authorization... 1 Drug Product(s) with Changes to Criteria for Coverage... 2 Added Product(s)... 2 New Established Interchangeable (IC) Grouping(s)... 3 Least Cost Alternative (LCA) Price Change(s)... 4 Product(s) with a Price Change... 4 Discontinued Listing(s)... 5 Part 2 Drug Additions Part 3 Special Authorization EFFECTIVE DECEMBER 1, 2018
4 UPDATES TO THE ALBERTA DRUG BENEFIT LIST Special Authorization The following drug product(s) will be considered for coverage by Special Authorization for patients covered under Alberta government-sponsored drug programs. New Drug Product(s) Available by Special Authorization Trade Name / Strength / Form Generic Description DIN MFR BRIVLERA 10 MG TABLET BRIVARACETAM UCB BRIVLERA 25 MG TABLET BRIVARACETAM UCB BRIVLERA 50 MG TABLET BRIVARACETAM UCB BRIVLERA 75 MG TABLET BRIVARACETAM UCB BRIVLERA 100 MG TABLET BRIVARACETAM UCB HEMANGIOL 3.75 MG / ML ORAL SOLUTION PROPRANOLOL HCL PIE LANCORA 5 MG TABLET IVABRADINE HYDROCHLORIDE SEV LANCORA 7.5 MG TABLET IVABRADINE HYDROCHLORIDE SEV QUINSAIR 100 MG / ML INHALATION SOLUTION LEVOFLOXACIN RAP SPINRAZA 2.4 MG / ML INJECTION NUSINERSEN SODIUM BIO Additional Brand(s) and/or Strength(s) of Drug Product(s) Available by Special Authorization Trade Name / Strength / Form Generic Description DIN MFR O-LACOSAMIDE 50 MG TABLET LACOSAMIDE O-LACOSAMIDE 100 MG TABLET LACOSAMIDE O-LACOSAMIDE 150 MG TABLET LACOSAMIDE O-LACOSAMIDE 200 MG TABLET LACOSAMIDE PHARMA-LACOSAMIDE 50 MG TABLET LACOSAMIDE PHARMA-LACOSAMIDE 100 MG TABLET LACOSAMIDE PHARMA-LACOSAMIDE 150 MG TABLET LACOSAMIDE PHARMA-LACOSAMIDE 200 MG TABLET LACOSAMIDE SANDOZ LACOSAMIDE 50 MG TABLET LACOSAMIDE SANDOZ LACOSAMIDE 100 MG TABLET LACOSAMIDE SANDOZ LACOSAMIDE 150 MG TABLET LACOSAMIDE SANDOZ LACOSAMIDE 200 MG TABLET LACOSAMIDE A-LACOSAMIDE 50 MG TABLET LACOSAMIDE A-LACOSAMIDE 100 MG TABLET LACOSAMIDE A-LACOSAMIDE 150 MG TABLET LACOSAMIDE A-LACOSAMIDE 200 MG TABLET LACOSAMIDE EFFECTIVE DECEMBER 1,
5 UPDATES TO THE ALBERTA DRUG BENEFIT LIST Drug Product(s) with Changes to Criteria for Coverage Trade Name / Strength / Form Generic Description DIN MFR CAYSTON 75 MG / VIAL INHALATION POWDER FOR SOLUTION AZTREONAM GIL Added Product(s) Trade Name / Strength / Form Generic Description DIN MFR ACTIKERALL 0.5 % / 10 % TOPICAL SOLUTION 5-FLUOROURACIL/ SALICYLIC ACID CIP APO-HYDROMORPHONE CR 3 MG CONTROLLED-RELEASE CAPSULE APO-HYDROMORPHONE CR 4.5 MG CONTROLLED-RELEASE CAPSULE APO-HYDROMORPHONE CR 6 MG CONTROLLED-RELEASE CAPSULE APO-HYDROMORPHONE CR 9 MG CONTROLLED-RELEASE CAPSULE APO-HYDROMORPHONE CR 18 MG CONTROLLED-RELEASE CAPSULE APO-HYDROMORPHONE CR 24 MG CONTROLLED-RELEASE CAPSULE APO-HYDROMORPHONE CR 30 MG CONTROLLED-RELEASE CAPSULE HYDROMORPHONE HCL APX HYDROMORPHONE HCL APX HYDROMORPHONE HCL APX HYDROMORPHONE HCL APX HYDROMORPHONE HCL APX HYDROMORPHONE HCL APX HYDROMORPHONE HCL APX O-DUTASTERIDE 0.5 MG CAPSULE DUTASTERIDE O-TRANDOLAPRIL 0.5 MG CAPSULE TRANDOLAPRIL O-TRANDOLAPRIL 1 MG CAPSULE TRANDOLAPRIL O-TRANDOLAPRIL 2 MG CAPSULE TRANDOLAPRIL O-TRANDOLAPRIL 4 MG CAPSULE TRANDOLAPRIL BACLOFEN 0.05 MG / ML INJECTION BACLOFEN TGT BACLOFEN 0.5 MG / ML INJECTION BACLOFEN TGT BACLOFEN 2 MG / ML INJECTION BACLOFEN TGT DYSPORT THERAPEUTIC 300 IU / VIAL INJECTION ABOBOTULINUMTOXINA ISP DYSPORT THERAPEUTIC 500 IU / VIAL INJECTION ABOBOTULINUMTOXINA ISP ENSTILAR 50 MCG / G / 0.5 MG / G TOPICAL FOAM CALCIPOTRIOL MONOHYDRATE/ BETAMETHASONE DIPROPIONATE LEO JAMP-PREGABALIN 25 MG CAPSULE PREGABALIN JPC JAMP-PREGABALIN 50 MG CAPSULE PREGABALIN JPC JAMP-PREGABALIN 75 MG CAPSULE PREGABALIN JPC JAMP-PREGABALIN 150 MG CAPSULE PREGABALIN JPC 2 EFFECTIVE DECEMBER 1, 2018
6 Added Product(s), continued UPDATES TO THE ALBERTA DRUG BENEFIT LIST Trade Name / Strength / Form Generic Description DIN MFR JAMP-URSODIOL 250 MG TABLET URSODIOL JPC JAMP-URSODIOL 500 MG TABLET URSODIOL JPC MAR-METHIMAZOLE 5 MG TABLET THIAMAZOLE MAR MINT-CANDESARTAN 8 MG TABLET CANDESARTAN CILEXETIL MPI MINT-CANDESARTAN 16 MG TABLET CANDESARTAN CILEXETIL MPI MINT-FUROSEMIDE 20 MG TABLET FUROSEMIDE MPI MINT-FUROSEMIDE 40 MG TABLET FUROSEMIDE MPI ONDANSETRON USP 2 MG / ML INJECTION ONDANSETRON HCL DIHYDRATE STM A-TRANDOLAPRIL 0.5 MG CAPSULE TRANDOLAPRIL A-TRANDOLAPRIL 1 MG CAPSULE TRANDOLAPRIL A-TRANDOLAPRIL 2 MG CAPSULE TRANDOLAPRIL A-TRANDOLAPRIL 4 MG CAPSULE TRANDOLAPRIL TRESIBA FLEXTOUCH PEN 100 UNIT / ML INJECTION INSULIN DEGLUDEC NNA TRESIBA FLEXTOUCH PEN 200 UNIT / ML INJECTION INSULIN DEGLUDEC NNA New Established Interchangeable (IC) Grouping(s) The following IC Grouping(s) have been established and LCA pricing will be applied effective January 1, Generic Description Strength / Form New LCA Price HYDROMORPHONE HCL 3 MG CONTROLLED-RELEASE CAPSULE HYDROMORPHONE HCL 4.5 MG CONTROLLED-RELEASE CAPSULE HYDROMORPHONE HCL 6 MG CONTROLLED-RELEASE CAPSULE HYDROMORPHONE HCL 9 MG CONTROLLED-RELEASE CAPSULE HYDROMORPHONE HCL 18 MG CONTROLLED-RELEASE CAPSULE HYDROMORPHONE HCL 24 MG CONTROLLED-RELEASE CAPSULE HYDROMORPHONE HCL 30 MG CONTROLLED-RELEASE CAPSULE LACOSAMIDE 50 MG TABLET LACOSAMIDE 100 MG TABLET LACOSAMIDE 150 MG TABLET LACOSAMIDE 200 MG TABLET THIAMAZOLE 5 MG TABLET EFFECTIVE DECEMBER 1,
7 UPDATES TO THE ALBERTA DRUG BENEFIT LIST Least Cost Alternative (LCA) Price Change(s) The following established IC Grouping(s) are affected and a revised LCA price has been established. Groupings affected by a Price Decrease, will be effective January 1, Please review the online Alberta Drug Benefit List at for further information. Generic Description Strength / Form New LCA Price BACLOFEN 0.05 MG / ML INJECTION BACLOFEN 0.5 MG / ML INJECTION BACLOFEN 2 MG / ML INJECTION FUROSEMIDE 20 MG TABLET FUROSEMIDE 40 MG TABLET TRANDOLAPRIL 0.5 MG CAPSULE TRANDOLAPRIL 1 MG CAPSULE TRANDOLAPRIL 2 MG CAPSULE TRANDOLAPRIL 4 MG CAPSULE URSODIOL 250 MG TABLET URSODIOL 500 MG TABLET Product(s) with a Price Change The following product(s) had a Price Decrease. The previous higher price will be recognized until December 31, For products within an established IC Grouping, the LCA price may apply. Trade Name / Strength / Form Generic Description DIN MFR APO-FUROSEMIDE 20 MG TABLET FUROSEMIDE APX APO-FUROSEMIDE 40 MG TABLET FUROSEMIDE APX BACLOFEN INTRATHECAL 0.05 MG / ML INJECTION BACLOFEN STM BACLOFEN INTRATHECAL 0.5 MG / ML INJECTION BACLOFEN STM BACLOFEN INTRATHECAL 2 MG / ML INJECTION BACLOFEN STM FUROSEMIDE 20 MG TABLET FUROSEMIDE SNS FUROSEMIDE 40 MG TABLET FUROSEMIDE SNS -TRANDOLAPRIL 0.5 MG CAPSULE TRANDOLAPRIL TRANDOLAPRIL 1 MG CAPSULE TRANDOLAPRIL TRANDOLAPRIL 2 MG CAPSULE TRANDOLAPRIL TRANDOLAPRIL 4 MG CAPSULE TRANDOLAPRIL URSODIOL C 250 MG TABLET URSODIOL URSODIOL C 500 MG TABLET URSODIOL SANDOZ TRANDOLAPRIL 0.5 MG CAPSULE TRANDOLAPRIL EFFECTIVE DECEMBER 1, 2018
8 UPDATES TO THE ALBERTA DRUG BENEFIT LIST Product(s) with a Price Change, continued Trade Name / Strength / Form Generic Description DIN MFR SANDOZ TRANDOLAPRIL 1 MG CAPSULE TRANDOLAPRIL SANDOZ TRANDOLAPRIL 2 MG CAPSULE TRANDOLAPRIL SANDOZ TRANDOLAPRIL 4 MG CAPSULE TRANDOLAPRIL A-FUROSEMIDE 20 MG TABLET FUROSEMIDE A-FUROSEMIDE 40 MG TABLET FUROSEMIDE URSODIOL TABLETS USP 250 MG TABLET URSODIOL GLM URSODIOL TABLETS USP 500 MG TABLET URSODIOL GLM Discontinued Listing(s) Notification of discontinuation has been received from the manufacturer(s). The Alberta government-sponsored drug programs previously covered the following drug product(s). Effective December 1, 2018, the listed product(s) will no longer be a benefit and will not be considered for coverage by Special Authorization. A transition period will be applied and, as of January 1, 2019 claims will no longer pay for these product(s). Trade Name / Strength / Form Generic Description DIN MFR APO-CYCLOSPORINE 100 MG / ML ORAL SOLUTION CYCLOSPORINE APX APO-LACTULOSE 667 MG / ML ORAL SYRUP LACTULOSE APX HOLKIRA PAK 12.5 MG / 75 MG / 50 MG / 250 MG TABLET OMBITASVIR/ PARITAPREVIR/ RITONAVIR/ DASABUVIR SODIUM MONOHYDRATE ABV MYLAN-ALPRAZOLAM 0.25 MG TABLET ALPRAZOLAM MYP PDP-PROCYCLIDINE 0.5 MG / ML ORAL ELIXIR PROCYCLIDINE HCL PPH PDP-PROCYCLIDINE 2.5 MG TABLET PROCYCLIDINE HCL PPH PDP-PROCYCLIDINE 5 MG TABLET PROCYCLIDINE HCL PPH EFFECTIVE DECEMBER 1,
9 Drug Additions PART 2 Drug Additions
10 ALBERTA DRUG BENEFIT LIST UPDATE 5-FLUOROURACIL/ SALICYLIC ACID 0.5 % * 10 % TOPICAL SOLUTION ACTIKERALL CIP ABOBOTULINUMTOXINA 300 IU / VIAL INJECTION DYSPORT THERAPEUTIC 500 IU / VIAL INJECTION DYSPORT THERAPEUTIC ISP ISP BACLOFEN 0.05 MG / ML INJECTION BACLOFEN INJECTION BACLOFEN INTRATHECAL LIORESAL INTRATHECAL 0.5 MG / ML INJECTION BACLOFEN INJECTION BACLOFEN INTRATHECAL LIORESAL INTRATHECAL 2 MG / ML INJECTION BACLOFEN INJECTION BACLOFEN INTRATHECAL LIORESAL INTRATHECAL TGT STM NOV TGT STM NOV TGT STM NOV CANDESARTAN CILEXETIL 8 MG ORAL TABLET APO-CANDESARTAN O-CANDESARTAN CANDESARTAN CANDESARTAN CANDESARTAN CILEXETIL JAMP-CANDESARTAN MINT-CANDESARTAN CANDESARTAN RAN-CANDESARTAN SANDOZ CANDESARTAN A-CANDESARTAN ATACAND 16 MG ORAL TABLET APO-CANDESARTAN CANDESARTAN CANDESARTAN CANDESARTAN CILEXETIL JAMP-CANDESARTAN MINT-CANDESARTAN -CANDESARTAN RAN-CANDESARTAN SANDOZ CANDESARTAN A-CANDESARTAN ATACAND APX SIV SNS AHI JPC MPI RAN AZC APX SIV SNS AHI JPC MPI RAN AZC The DBL is not a prescribing or a diagnostic tool. Prescribers should refer to drug monographs and utilize professional judgment. UNIT OF ISSUE - REFER TO PRICE POLICY 2. 1 EFFECTIVE DECEMBER 1, 2018
11 ALBERTA DRUG BENEFIT LIST UPDATE DUTASTERIDE 0.5 MG ORAL CAPSULE ACT DUTASTERIDE APO-DUTASTERIDE O-DUTASTERIDE DUTASTERIDE DUTASTERIDE MED-DUTASTERIDE MINT-DUTASTERIDE DUTASTERIDE SANDOZ DUTASTERIDE A-DUTASTERIDE AVODART APH APX SIV SNS GMP MPI GSK FUROSEMIDE 20 MG ORAL TABLET APO-FUROSEMIDE FUROSEMIDE MINT-FUROSEMIDE A-FUROSEMIDE 40 MG ORAL TABLET APO-FUROSEMIDE FUROSEMIDE MINT-FUROSEMIDE A-FUROSEMIDE APX SNS MPI APX SNS MPI INSULIN DEGLUDEC 100 U/ML / ML INJECTION TRESIBA FLEXTOUCH PEN 200 U/ML / ML INJECTION TRESIBA FLEXTOUCH PEN NNA NNA ONDANSETRON HCL DIHYDRATE 2 MG / ML (BASE) INJECTION JAMP-ONDANSETRON (PRESERVATIVE FREE) ONDANSETRON (PRESERVATIVE FREE) ONDANSETRON (UNPRESERVED) ONDANSETRON INJECTION USP ZOFRAN JPC MYP STM NOV The DBL is not a prescribing or a diagnostic tool. Prescribers should refer to drug monographs and utilize professional judgment. PRODUCT IS NOT INTERCHANGEABLE 2. 2 EFFECTIVE DECEMBER 1, 2018
12 ALBERTA DRUG BENEFIT LIST UPDATE PREGABALIN 25 MG ORAL CAPSULE APO-PREGABALIN O-PREGABALIN JAMP-PREGABALIN MINT-PREGABALIN PREGABALIN PREGABALIN PREGABALIN RAN-PREGABALIN SANDOZ PREGABALIN A-PREGABALIN 50 MG ORAL CAPSULE APO-PREGABALIN O-PREGABALIN JAMP-PREGABALIN MINT-PREGABALIN PREGABALIN PREGABALIN PREGABALIN RAN-PREGABALIN SANDOZ PREGABALIN A-PREGABALIN 75 MG ORAL CAPSULE APO-PREGABALIN O-PREGABALIN JAMP-PREGABALIN MINT-PREGABALIN PREGABALIN PREGABALIN PREGABALIN RAN-PREGABALIN SANDOZ PREGABALIN A-PREGABALIN 150 MG ORAL CAPSULE APO-PREGABALIN O-PREGABALIN JAMP-PREGABALIN MINT-PREGABALIN -PREGABALIN PREGABALIN PREGABALIN RAN-PREGABALIN SANDOZ PREGABALIN A-PREGABALIN APX JPC MPI SIV SNS RAN APX JPC MPI SIV SNS RAN APX JPC MPI SIV SNS RAN APX JPC MPI SIV SNS RAN THIAMAZOLE 5 MG ORAL TABLET MAR-METHIMAZOLE TAPAZOLE MAR PAL The DBL is not a prescribing or a diagnostic tool. Prescribers should refer to drug monographs and utilize professional judgment. UNIT OF ISSUE - REFER TO PRICE POLICY 2. 3 EFFECTIVE DECEMBER 1, 2018
13 ALBERTA DRUG BENEFIT LIST UPDATE TRANDOLAPRIL 0.5 MG ORAL CAPSULE O-TRANDOLAPRIL TRANDOLAPRIL SANDOZ TRANDOLAPRIL A-TRANDOLAPRIL MAVIK 1 MG ORAL CAPSULE O-TRANDOLAPRIL TRANDOLAPRIL SANDOZ TRANDOLAPRIL A-TRANDOLAPRIL MAVIK 2 MG ORAL CAPSULE O-TRANDOLAPRIL TRANDOLAPRIL SANDOZ TRANDOLAPRIL A-TRANDOLAPRIL MAVIK 4 MG ORAL CAPSULE O-TRANDOLAPRIL -TRANDOLAPRIL SANDOZ TRANDOLAPRIL A-TRANDOLAPRIL MAVIK BGP BGP BGP BGP URSODIOL 250 MG ORAL TABLET JAMP-URSODIOL URSODIOL C URSODIOL TABLETS USP URSO 500 MG ORAL TABLET JAMP-URSODIOL -URSODIOL C URSODIOL TABLETS USP URSO DS JPC GLM AXC JPC GLM AXC The DBL is not a prescribing or a diagnostic tool. Prescribers should refer to drug monographs and utilize professional judgment. PRODUCT IS NOT INTERCHANGEABLE 2. 4 EFFECTIVE DECEMBER 1, 2018
14 Special Authorization PART 3 Special Authorization
15 ALBERTA DRUG BENEFIT LIST UPDATE CRITERIA FOR SPECIAL AUTHORIZATION OF SELECT DRUG PRODUCTS AZTREONAM The drug product(s) listed below are eligible for coverage via the step therapy/special authorization process. FIRST-LINE DRUG PRODUCT(S): TOBRAMYCIN INHALATION SOLUTION "For the treatment of chronic pulmonary Pseudomonas aeruginosa infections when used as cyclic treatment (28-day cycles) in patients 6 years of age and older with moderate to severe cystic fibrosis (CF) and deteriorating clinical condition despite treatment with inhaled tobramycin. Coverage will not be considered when inhaled aztreonam and other inhaled antibiotic(s) (e.g. levofloxacin, tobramycin) are intended for use in combination. Special authorization may be granted for 6 months." Note: If a claim for the Step therapy drug product is rejected, pharmacists can use their professional judgment to determine the appropriateness of using the intervention code(s) noted below to re-submit a claim. The pharmacist is responsible to document on the patient's record the rationale for using the second-line therapy drug. UP - First-line therapy ineffective UQ - First-line therapy not tolerated 75 MG / VIAL INHALATION POWDER FOR SOLUTION CAYSTON GIL BRIVARACETAM "For adjunctive therapy in patients with refractory partial-onset seizures who meet all of the following criteria: - Are currently receiving two or more antiepileptic medications, AND - Have failed or demonstrated intolerance to three other antiepileptic medications, AND - Patients are not receiving concurrent therapy with levetiracetam, AND, - Therapy must be initiated by a Neurologist. For the purpose of administering these criteria failure is defined as inability to achieve satisfactory seizure control. Special authorization may be granted for six months. Coverage cannot be provided for brivaracetam, eslicarbazepine, lacosamide or perampanel when these medications are intended for use in combination." Each of these products is eligible for auto-renewal. 10 MG ORAL TABLET BRIVLERA 25 MG ORAL TABLET BRIVLERA 50 MG ORAL TABLET BRIVLERA 75 MG ORAL TABLET BRIVLERA 100 MG ORAL TABLET BRIVLERA UCB UCB UCB UCB UCB The DBL is not a prescribing or a diagnostic tool. Prescribers should refer to drug monographs and utilize professional judgment. UNIT OF ISSUE - REFER TO PRICE POLICY 3. 1 EFFECTIVE DECEMBER 1, 2018
16 ALBERTA DRUG BENEFIT LIST UPDATE CRITERIA FOR SPECIAL AUTHORIZATION OF SELECT DRUG PRODUCTS IVABRADINE HYDROCHLORIDE "For the treatment of heart failure (HF) in patients with the following criteria: 1) Reduced left ventricular ejection fraction (LVEF) (less than or equal to 35%) And 2) New York Heart Association (NYHA) class II or III HF symptoms despite at least FOUR weeks of optimal treatment with: - a stable dose of an angiotensin converting enzyme inhibitor (ACEI) or an angiotensin II receptor antagonist (ARB) - in combination with a beta-blocker and, if tolerated, a mineralocorticoid receptor antagonist (MRA) And 3) Who are in sinus rhythm with a resting heart rate greater than or equal to 77 beats per minute (bpm) on average using either an ECG on at least three separate visits or by continuous monitoring And 4) Who had at least one hospitalization due to HF in the last year For coverage, this drug must be initiated by a Specialist in Cardiology or Internal Medicine, and the initial request must be completed by the Specialist. Special authorization may be granted for six months." This product is eligible for auto-renewal. All requests (including renewal requests) for ivabradine hydrochloride must be completed using the Eplerenone/Ivabradine/Sacubitril+Valsartan Special Authorization Request Form (ABC 60050). 5 MG (BASE) ORAL TABLET LANCORA 7.5 MG (BASE) ORAL TABLET LANCORA SEV SEV The DBL is not a prescribing or a diagnostic tool. Prescribers should refer to drug monographs and utilize professional judgment. PRODUCT IS NOT INTERCHANGEABLE 3. 2 EFFECTIVE DECEMBER 1, 2018
17 ALBERTA DRUG BENEFIT LIST UPDATE CRITERIA FOR SPECIAL AUTHORIZATION OF SELECT DRUG PRODUCTS LACOSAMIDE "For adjunctive therapy in patients with refractory partial-onset seizures who meet all of the following criteria: - Are currently receiving two or more antiepileptic medications, AND - Have failed or demonstrated intolerance to three other antiepileptic medications, AND - Therapy must be initiated by a Neurologist. For the purpose of administering these criteria failure is defined as inability to achieve satisfactory seizure control. Special authorization may be granted for six months. Coverage cannot be provided for eslicarbazepine, lacosamide or perampanel when these medications are intended for use in combination." Each of these products is eligible for auto-renewal. 50 MG ORAL TABLET O-LACOSAMIDE PHARMA-LACOSAMIDE SANDOZ LACOSAMIDE A-LACOSAMIDE VIMPAT 100 MG ORAL TABLET O-LACOSAMIDE PHARMA-LACOSAMIDE SANDOZ LACOSAMIDE A-LACOSAMIDE VIMPAT 150 MG ORAL TABLET O-LACOSAMIDE PHARMA-LACOSAMIDE SANDOZ LACOSAMIDE A-LACOSAMIDE VIMPAT 200 MG ORAL TABLET O-LACOSAMIDE PHARMA-LACOSAMIDE SANDOZ LACOSAMIDE A-LACOSAMIDE VIMPAT UCB UCB UCB UCB The DBL is not a prescribing or a diagnostic tool. Prescribers should refer to drug monographs and utilize professional judgment. UNIT OF ISSUE - REFER TO PRICE POLICY 3. 3 EFFECTIVE DECEMBER 1, 2018
18 ALBERTA DRUG BENEFIT LIST UPDATE CRITERIA FOR SPECIAL AUTHORIZATION OF SELECT DRUG PRODUCTS LEVOFLOXACIN The drug product(s) listed below are eligible for coverage via the step therapy/special authorization process. FIRST-LINE DRUG PRODUCT(S): TOBRAMYCIN INHALATION SOLUTION "For the treatment of chronic pulmonary Pseudomonas aeruginosa infections when used as cyclic treatment (28-day cycles) in patients 18 years of age and older with moderate to severe cystic fibrosis (CF) and deteriorating clinical condition despite treatment with inhaled tobramycin." "Coverage will not be considered when inhaled levofloxacin and other inhaled antibiotic(s) (e.g. tobramycin, aztreonam) are intended for use in combination, either concurrently or for antibiotic cycling during off-treatment periods." "Special authorization may be granted for 6 months." Note: If a claim for the Step therapy drug product is rejected, pharmacists can use their professional judgment to determine the appropriateness of using the intervention code(s) noted below to re-submit a claim. The pharmacist is responsible to document on the patient's record the rationale for using the second-line therapy drug. UP - First-line therapy ineffective UQ - First-line therapy not tolerated 100 MG / ML INHALATION SOLUTION QUINSAIR RAP The DBL is not a prescribing or a diagnostic tool. Prescribers should refer to drug monographs and utilize professional judgment. PRODUCT IS NOT INTERCHANGEABLE 3. 4 EFFECTIVE DECEMBER 1, 2018
19 ALBERTA DRUG BENEFIT LIST UPDATE CRITERIA FOR SPECIAL AUTHORIZATION OF SELECT DRUG PRODUCTS NUSINERSEN SODIUM "For patients diagnosed with 5q Spinal Muscular Atrophy (SMA) Type 1 under the care of a specialist with experience in the diagnosis and management of SMA, if the following clinical criteria are met: - Genetic documentation of 5q SMA homozygous gene deletion, homozygous mutation, or compound heterozygote, AND - Genetic documentation of two copies of the survival motor neuron 2 (SMN2) gene, AND - Disease duration less than 26 weeks with onset of clinical signs and symptoms consistent with SMA after the first week after birth and on or before 7 months of age, AND - Patient is not currently requiring permanent invasive ventilation.* Initial coverage may be approved for three 12 mg doses at Day 0, Day 14 and Day 28, followed by one 12 mg dose at Day 63. Patients will be limited to receiving one dose of nusinersen per prescription at their pharmacy. For continued coverage, the patient must meet the following criteria: - there is demonstrated maintenance of motor milestone function (as assessed using the Hammersmith Infant Neurological Examination [HINE] Section 2) compared to pre-treatment baseline; OR - there is demonstrated improvement in motor milestone function (as assessed using the HINE Section 2) compared to pre-treatment baseline; AND - patient does not require permanent invasive ventilation*. Continued coverage may be considered for one 12 mg maintenance dose at a time, to be administered at 4-month intervals. Each maintenance dose cannot be considered prior to 4 months elapsing from the date of the previous dose. Treatment should be discontinued if, prior to the fifth dose or every subsequent dose of nusinersen, the above renewal criteria are not met. *Permanent invasive ventilation is defined as the use of tracheostomy and a ventilator due to progression of SMA that is not due to an identifiable and reversible cause. All requests (including renewal requests) for nusinersen must be completed using the Nusinersen Special Authorization Request Form (ABC 60064)." 2.4 MG / ML (BASE) INJECTION SPINRAZA BIO The DBL is not a prescribing or a diagnostic tool. Prescribers should refer to drug monographs and utilize professional judgment. UNIT OF ISSUE - REFER TO PRICE POLICY 3. 5 EFFECTIVE DECEMBER 1, 2018
20 ALBERTA DRUG BENEFIT LIST UPDATE CRITERIA FOR SPECIAL AUTHORIZATION OF SELECT DRUG PRODUCTS PROPRANOLOL HCL "For the treatment of proliferating infantile hemangioma requiring systemic therapy and at least one of the following: - Life- or function-threatening hemangioma, OR - Ulcerated hemangioma with pain and/or lack of response to simple wound care measures, OR - Hemangioma with a risk of permanent scarring or disfigurement. Special authorization may be granted for 12 months. Continued coverage may be approved for a period of 12 months for patients who are responding to therapy or experience relapse of symptoms after treatment discontinuation." 3.75 MG / ML ORAL SOLUTION HEMANGIOL PIE The DBL is not a prescribing or a diagnostic tool. Prescribers should refer to drug monographs and utilize professional judgment. PRODUCT IS NOT INTERCHANGEABLE 3. 6 EFFECTIVE DECEMBER 1, 2018
Updates to the Alberta Drug Benefit List. Effective September 1, 2018
Updates to the Alberta Drug Benefit List Effective September 1, 2018 Inquiries should be directed to: Pharmacy Services Alberta Blue Cross 10009 108 Street NW Edmonton AB T5J 3C5 Telephone Number: (780)
More informationUpdates to the Alberta Drug Benefit List. Effective November 1, 2018
Updates to the Alberta Drug Benefit List Effective November 1, 2018 Inquiries should be directed to: Pharmacy Services Alberta Blue Cross 10009 108 Street NW Edmonton AB T5J 3C5 Telephone Number: (780)
More informationUpdates to the Alberta Drug Benefit List. Effective August 1, 2018
Updates to the Alberta Drug Benefit List Effective August 1, 2018 Inquiries should be directed to: Pharmacy Services Alberta Blue Cross 10009 108 Street NW Edmonton AB T5J 3C5 Telephone Number: (780) 498-8370
More informationUpdates to the Alberta Drug Benefit List. Effective August 1, 2017
Updates to the Alberta Drug Benefit List Effective August 1, 2017 Inquiries should be directed to: Pharmacy Services Alberta Blue Cross 10009 108 Street NW Edmonton AB T5J 3C5 Telephone Number: (780) 498-8370
More informationUpdates to the Alberta Drug Benefit List. Effective July 1, 2018
Updates to the Alberta Drug Benefit List Effective July 1, 2018 Inquiries should be directed to: Pharmacy Services Alberta Blue Cross 10009 108 Street NW Edmonton AB T5J 3C5 Telephone Number: (780) 498-8370
More informationUpdates to the Alberta Drug Benefit List. Effective July 1, 2017
Updates to the Alberta Drug Benefit List Effective July 1, 2017 Inquiries should be directed to: Pharmacy Services Alberta Blue Cross 10009 108 Street NW Edmonton AB T5J 3C5 Telephone Number: (780) 498-8370
More informationUpdates to the Alberta Drug Benefit List. Effective October 1, 2017
Updates to the Alberta Drug Benefit List Effective October 1, 2017 Inquiries should be directed to: Pharmacy Services Alberta Blue Cross 10009 108 Street NW Edmonton AB T5J 3C5 Telephone Number: (780)
More informationUpdates to the Alberta Drug Benefit List. Effective January 1, 2018
Updates to the Alberta Drug Benefit List Effective January 1, 2018 Inquiries should be directed to: Pharmacy Services Alberta Blue Cross 10009 108 Street NW Edmonton AB T5J 3C5 Telephone Number: (780)
More informationPalliative Coverage Drug Benefit Supplement
Palliative Coverage Drug Benefit Supplement Effective April 1, 2017 Inquiries should be directed to: Pharmacy Services Alberta Blue Cross 10009 108 Street NW Edmonton AB T5J 3C5 Telephone Number: (780)
More informationUpdates to the Alberta Human Services Drug Benefit Supplement
Updates to the Alberta Human Services Drug Benefit Supplement Effective October 1, 2017 Inquiries should be directed to: Pharmacy Services Alberta Blue Cross 10009 108 Street NW Edmonton AB T5J 3C5 Telephone
More informationSummary of Changes to the Alberta Human Services Drug Benefit Supplement
Summary of Changes to the Alberta Human Services Drug Benefit Supplement Effective April 1, 2018 Inquiries should be directed to: Pharmacy Services Alberta Blue Cross 10009 108 Street NW Edmonton AB T5J
More informationUpdates to the Alberta Human Services Drug Benefit Supplement
Updates to the Alberta Human Services Drug Benefit Supplement Effective December 9, 2013 Inquiries should be directed to: Pharmacy Services Alberta Blue Cross 10009 108 Street NW Edmonton AB T5J 3C5 Telephone
More informationUpdates to the Alberta Drug Benefit List. Effective May 1, 2018
Updates to the Alberta Drug Benefit List Effective May 1, 2018 Inquiries should be directed to: Pharmacy Services Alberta Blue Cross 10009 108 Street NW Edmonton AB T5J 3C5 Telephone Number: (780) 498-8370
More informationUpdates to the Alberta Drug Benefit List. Effective August 1, 2014
Updates to the Alberta Drug Benefit List Effective August 1, 2014 Inquiries should be directed to: Pharmacy Services Alberta Blue Cross 10009 108 Street NW Edmonton AB T5J 3C5 Telephone Number: (780) 498-8370
More informationNova Scotia Pharmacare Programs Interchangeable Product Updates November 13, 2018 New Categories
PAGE 1 OF 7 Nova Scotia Pharmacare Programs Interchangeable Product Updates November 13, New Categories A Maximum Reimbursable Price (MRP) or Pharmacare Reimbursement Price (PRP) has been established for
More informationUpdates to the Alberta Health and Wellness Drug Benefit List
Updates to the Alberta Health and Wellness Drug Benefit List Effective May 1, 2012 UPDATES TO THE ALBERTA HEALTH AND WELLNESS DRUG BENEFIT LIST Inquiries should be directed to: Pharmacy Services Alberta
More informationSummary of Changes to the Alberta Human Services Drug Benefit Supplement
Summary of Changes to the Alberta Human Services Drug Benefit Supplement Effective April 1, 2012 Inquiries should be directed to: Pharmacy Services Alberta Blue Cross 10009 108 Street NW Edmonton AB T5J
More informationUpdates to the Alberta Drug Benefit List. Effective June 1, 2018
Updates to the Alberta Drug Benefit List Effective June 1, 2018 Inquiries should be directed to: Pharmacy Services Alberta Blue Cross 10009 108 Street NW Edmonton AB T5J 3C5 Telephone Number: (780) 498-8370
More informationUpdates to the Alberta Drug Benefit List. Effective February 1, 2018
Updates to the Alberta Drug Benefit List Effective February 1, 2018 Inquiries should be directed to: Pharmacy Services Alberta Blue Cross 10009 108 Street NW Edmonton AB T5J 3C5 Telephone Number: (780)
More informationOntario Drug Benefit Formulary/Comparative Drug Index
Ministry of Health and Long-Term Care Ontario Drug Benefit Formulary/Comparative Drug Index Edition 43 Summary of Changes December 2018 Effective December 21, 2018 Drug Programs Policy and Strategy Branch
More information20:00. Blood Formulation, Coagulation and Thrombosis. 20:00 Blood Formulation, Coagulation and Thrombosis
Blood Formulation, Coagulation and Thrombosis Blood Formulation, Coagulation and Thrombosis 20:04.04 ANTIANEMIA DRUGS (IRON PREPARATIONS) IRON DEXTRAN COMPLEX 50 MG / ML INJECTION 00002205963 DEXIRON LPI
More informationNB Drug Plans Formulary Update
Bulletin # 988 November 30, 2018 NB Drug Plans Formulary Update This update to the New Brunswick Drug Plans Formulary is effective November 30, 2018. Included in this bulletin: Regular Benefit Additions
More informationAlberta Human Services Drug Benefit Supplement
Alberta Human Services Drug Benefit Supplement Effective April 1, 2018 Inquiries should be directed to: Pharmacy Services Alberta Blue Cross 10009 108 Street NW Edmonton, AB T5J 3C5 Telephone Number: (780)
More informationPalliative Care Drug Benefit Supplement
Palliative Care Drug Benefit Supplement Effective April 1, 2007 Inquiries Inquiries should be directed to: Pharmacy Services Alberta Blue Cross 10009 108 Street NW Edmonton AB T5J 3C5 Telephone Number:
More informationBENEFIT STATUS PRODUCT STRENGTH DIN PRESCRIBER MFR
DECEMBER 2018 Nova Scotia Formulary Updates Smoking Cessation Therapies New Exception Status Benefits Invega Trinza (paliperidone palmitate) Synjardy (empaglifozin/ metformin Lancora (ivabradine Criteria
More informationSpinraza (Nusinersen) Drug Prior Authorization Protocol (Medical Benefit & Part B Benefit)
Line of Business: All Lines of Business Effective Date: August 16, 2017 Spinraza (Nusinersen) Drug Prior Authorization Protocol (Medical Benefit & Part B Benefit) This policy has been developed through
More informationOntario Drug Benefit Formulary/Comparative Drug Index
Ministry of Health and Long-Term Care Ontario Drug Benefit Formulary/Comparative Drug Index Edition 43 Summary of Changes June 2018 Effective June 29, 2018 Drug Programs Policy and Strategy Branch Ontario
More informationUpdates to the Alberta Drug Benefit List. Effective March 1, 2018
Updates to the Alberta Drug Benefit List Effective March 1, 2018 Inquiries should be directed to: Pharmacy Services Alberta Blue Cross 10009 108 Street NW Edmonton AB T5J 3C5 Telephone Number: (780) 498-8370
More informationNB Drug Plans Formulary Update
Bulletin # 995 March 27, 2019 NB Drug Plans Formulary Update This update to the New Brunswick Drug Plans Formulary is effective March 27, 2019. Included in this bulletin: Special Authorization Benefit
More informationOntario Drug Benefit Formulary/Comparative Drug Index
Ministry of Health and Long-Term Care Ontario Drug Benefit Formulary/Comparative Drug Index Edition 43 Summary of Changes August 2018 Effective August 30, 2018 Drug Programs Policy and Strategy Branch
More informationOntario Drug Benefit Formulary/Comparative Drug Index
Ministry of Health and Long-Term Care Ontario Drug Benefit Formulary/Comparative Drug Index Edition 43 Summary of Changes October 2018 Effective October 31, 2018 Drug Programs Policy and Strategy Branch
More informationManager, PEI Drug Programs Date : December 7, 2009 Tel / Tél : (902) Fax / Téléc : (902)
DRAFT To / Destinataire : All Retail Pharmacists and Staff From / Expéditeur : Faye Campbell Manager, PEI Drug Programs Date : December 7, 2009 Tel / Tél : (902) 368-6338 Fax / Téléc : (902) 368-4905 Subject
More informationSECTION 3. Section 3 Criteria for Special Authorization of Select Drug Products
SECTION 3 Criteria for Special Authorization of Select Drug Products Section 3 Criteria for Special Authorization of Select Drug Products CRITERIA FOR SPECIAL AUTHORIZATION OF SELECT DRUG PRODUCTS The
More informationPrior Authorization Update: Nusinersen
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationBENEFIT STATUS MFR PRODUCT STRENGTH DIN PRESCRIBER
DECEMBER 2018 Nova Scotia Formulary Updates Smoking Cessation Therapies New Exception Status Benefits Invega Trinza (paliperidone palmitate) Synjardy (empaglifozin/ metformin hydrochloride) Lancora (ivabradine
More informationNB Drug Plans Formulary Update
Bulletin # 914 October 14, 2015 NB Drug Plans Formulary Update This update to the New Brunswick Drug Plans Formulary is effective October 14, 2015. Included in this bulletin: Special Authorization Benefit
More informationOntario Drug Benefit Formulary/Comparative Drug Index
Ontario Drug Benefit Formulary/Comparative Drug Index Edition 42 Summary of Changes - July 2014 Effective July 30, 2014 Ministry of Health and Long-Term Care Table of Contents New Single Source Products...
More informationWhat s New in Heart Failure? Marie-France Gauthier, BSc, PharmD, ACPR Clinical Pharmacist at Montfort Hospital
What s New in Heart Failure? Marie-France Gauthier, BSc, PharmD, ACPR Clinical Pharmacist at Montfort Hospital Disclosures I have no current or past relationships with commercial entities Learning objectives
More informationOntario Drug Benefit Formulary/Comparative Drug Index
Ministry of Health and Long-Term Care Ontario Drug Benefit Formulary/Comparative Drug Index Edition 42 Summary of Changes July 2016 Effective July 28, 2016 Drug Programs Policy and Strategy Branch Ontario
More informationNB Drug Plans Formulary Update
Bulletin #984 October 31, 2018 NB Drug Formulary Update Drug product updates included in this bulletin: Drug product additions - New generic products will be reimbursed up to the category Maximum Allowable
More informationOntario Drug Benefit Formulary/Comparative Drug Index
Ministry of Health and Long-Term Care Ontario Drug Benefit Formulary/Comparative Drug Index Edition 43 Summary of Changes February 2019 Effective February 28, 2019 Drug Programs Policy and Strategy Branch
More informationClinical Policy: Nusinersen (Spinraza) Reference Number: CP.PHAR.327
Clinical Policy: (Spinraza) Reference Number: CP.PHAR.327 Effective Date: 03/17 Last Review Date: 03/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Nusinersen (Spinraza) Reference Number: CP.PHAR.327 Effective Date: 10.01.18 Last Review Date: 07.13.18 Line of Business: Oregon Health Plan Coding Implications Revision Log See Important
More informationCORLANOR (ivabradine) oral tablet
CORLANOR (ivabradine) oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy Coverage
More informationCADTH Canadian Drug Expert Committee Recommendation
CADTH COMMON DRUG REVIEW CADTH Canadian Drug Expert Committee Recommendation (FINAL) Nusinersen (Spinraza Biogen Canada Inc.) Indication: Treatment of 5q Spinal Muscular Atrophy RECOMMENDATION: The CADTH
More informationSPINRAZA (NUSINERSEN)
SPINRAZA (NUSINERSEN) UnitedHealthcare Commercial Medical Benefit Drug Policy Policy Number: 2018D0059D Effective Date: April 1, 2018 Table of Contents Page INSTRUCTIONS FOR USE... 1 BENEFIT CONSIDERATIONS...
More informationBULLETIN # 89. Manitoba Drug Benefits and Interchangeability Formulary Amendments. The following amendments will take effect on October 20, 2016
BULLETIN # 89 Manitoba Drug Benefits and Interchangeability Formulary Amendments The following amendments will take effect on October 20, 2016 The amended Manitoba Specified Drug Regulation and Drug Interchangeability
More informationTherapeutic Substitution Service - Proton Pump Inhibitors (PPIs)
FEBRUARY 2014 Nova Scotia Pharmacare Programs Updates Therapeutic Substitution Service - Proton Pump Inhibitors (PPIs) Prescription Adaptation Minimum Days' Supply Nova Scotia Formulary Updates Pan-Canadian
More informationClinical Policy Bulletin: Nusinersen (Spinraza)
Clinical Policy Bulletin: Nusinersen (Spinraza) Number: 0915 Policy *Pleasesee amendment forpennsylvaniamedicaidattheendofthiscpb. Note: REQUIRES PRECERTIFICATION.Footnotes for Precertification of nusinersen
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Spinraza) Reference Number: CP.PHAR.327 Effective Date: 11.28.17 Last Review Date: 02.18 Line of Business: Commercial, Medicaid Coding Implications Revision Log See Important Reminder
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Neprilysin Inhibitor (Entresto ) Page 1 of 6 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Neprilysin Inhibitor (Entresto ) Prime Therapeutics will review Prior
More informationSASKATCHEWAN FORMULARY BULLETIN. Update to the 60th Edition of the Saskatchewan Formulary
Saskatchewan Ministry of Health July 1, 2010 Drug Plan and Extended Benefits Branch Bulletin #124 ISSN 1923-077X SASKATCHEWAN FORMULARY BULLETIN Update to the 60th Edition of the Saskatchewan Formulary
More informationSpinraza (nusinersen)
Spinraza (nusinersen) Policy Number: 5.02.540 Last Review: 04/2018 Origination: 03/2017 Next Review: 04/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for Spinraza
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: nusinersen_spinraza 03/2017 10/2017 10/2018 10/2017 Description of Procedure or Service Spinal muscular atrophy
More informationSummary of Changes to the Alberta Drug Benefit List
Summary of Changes to the Alberta Drug Benefit List Effective April 1, 2018 Inquiries should be directed to: Pharmacy Services Alberta Blue Cross 10009 108 Street NW Edmonton AB T5J 3C5 Telephone Number:
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: nusinersen_spinraza 03/2017 10/2018 10/2019 10/2018 Description of Procedure or Service Spinal muscular atrophy
More informationUPDATE AU Ontario Drug Benefit Formulary/Comparative Drug Index No. 41 Effective May 31, 2013 SUMMARY OF CHANGES
UPDATE AU Ontario Drug Benefit Formulary/Comparative Drug Index No. 41 Effective May 31, 2013 SUMMARY OF CHANGES TABLE OF CONTENTS Page New Multi-Source Drug(s) 2 Off Formulary Interchangeable Product(s)
More informationBULLETIN # 79. Manitoba Drug Benefits and Interchangeability Formulary Amendments. The following amendments will take effect on October 16, 2014
BULLETIN # 79 Manitoba Drug Benefits and Interchangeability Formulary Amendments The following amendments will take effect on October 16, 2014 The amended Manitoba Specified Drug Regulation and Drug Interchangeability
More informationNon-Insured Health Benefits
Winter 2017 Non-Insured Health Benefits First Nations and Inuit Health Branch Updates to the Drug Benefit List The Non-Insured Health Benefits (NIHB) Program provides supplementary health benefits, including
More information12:00 Autonomic Drugs 12:00. Autonomic Drugs
Autonomic Drugs Autonomic Drugs 12:04 PARASYMPATHOMIMETIC (CHOLINERGIC) AGENTS PILOCARPINE HCL 5 MG ORAL TABLET 00002216345 SALAGEN 1.4298 PYRIDOSTIGMINE BROMIDE 60 MG ORAL TABLET 00000869961 MESTINON
More informationOntario Drug Benefit Formulary/Comparative Drug Index
Ontario Drug Benefit Formulary/Comparative Drug Index Edition 42 Summary of Changes - November 2014 Effective November 27, 2014 Ministry of Health and Long-Term Care Table of Contents New Single Source
More informationNB Drug Plans Formulary Update
Bulletin #973 April 30, 2018 NB Drug Plans Formulary Update Generic drug product updates included in this bulletin: Generic drug product additions - New generic products will be reimbursed up to the category
More informationSaudi Heart Failure Guidelines. Waleed AlHabeeb, MD, MHA Consultant Heart Failure Cardiologist President of the Saudi Heart Failure Group
Saudi Heart Failure Guidelines Waleed AlHabeeb, MD, MHA Consultant Heart Failure Cardiologist President of the Saudi Heart Failure Group Heart Failure Expert committee The Heart Failure Expert Committee,
More informationA BULLETIN FOR PHARMACY SERVICE PROVIDERS FROM ALBERTA BLUE CROSS. Pan-Canadian Select Molecule Price Initiative for Generic Drugs
Pharmacy Benefact A BULLETIN FOR PHARMACY SERVICE PROVIDERS FROM ALBERTA BLUE CROSS Number 723 February 2018 Pan-Canadian Select Molecule Price Initiative for Generic Drugs Alberta Drug Benefit List prices
More informationUPDATE AA Ontario Drug Benefit Formulary/Comparative Drug Index No. 41 Effective September 15, 2011 SUMMARY OF CHANGES
UPDATE AA Ontario Drug Benefit Formulary/Comparative Drug Index No. 41 Effective September 15, 2011 SUMMARY OF CHANGES TABLE OF CONTENTS Page New Single Source Drug(s) 2 New Multi-Source Drug(s) 3 Off
More informationOntario Drug Benefit Formulary/Comparative Drug Index
Ontario Drug Benefit Formulary/Comparative Drug Index Edition 42 Summary of Changes - August 2015 Effective August 26, 2015 Ministry of Health and Long-Term Care Table of Contents New Single Source Products...
More informationLetter of Medical Necessity The Use of SPINRAZA (nusinersen) for Spinal Muscular Atrophy
TEMPLATE Letter of Medical Necessity The Use of SPINRAZA (nusinersen) for Spinal Muscular Atrophy Date: [Insert Name of Medical Director] RE: Patient Name [ ] [Insurance Company] Policy Number [ ] [Address]
More informationNew Exception Status Benefits
SEPTEMBER 2015 Nova Scotia Formulary Updates New Exception Status Benefits Holkira Pak (ombitasvir/paritaprevir/ ritonavir and dasabuvir) Moderiba (ribavirin) Abilify Maintena (aripiprazole) Invokana (canagliflozin)
More informationFrequent Dispensing Frequently Asked Questions
What is the Frequent Dispensing Policy? The frequent dispensing policy covers a maximum number of dispensing fees for prescriptions filled daily or in 2 to 27 day supplies. The current policies regulating
More informationSASKATCHEWAN FORMULARY BULLETIN Update to the 62nd Edition of the Saskatchewan Formulary
April 1, 2018 Bulletin #169 ISSN 1923-0761 SASKATCHEWAN FORMULARY BULLETIN Update to the 62nd Edition of the Saskatchewan Formulary Recommended as a full Formulary benefit: benztropine mesylate, tablet,
More information84:00. Skin and Mucous Membrane Agents. 84:00 Skin and Mucous Membrane Agents
Skin and Mucous Membrane Agents Skin and Mucous Membrane Agents COMPOUND PRESCRIPTION 00000999119 00000999112 COMPOUND - RETINOIC ACID (TRETINOIN) () MISCELLANEOUS COMPOUND To be used when the compound
More information*NOTE: When submitting CPT code and 99239, it is recommended the measure be submitted each time the code is submitted for hospital discharge.
Quality ID #5 (NQF 0081): Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD) National Quality
More informationNeprilysin Inhibitor (Entresto ) Prior Authorization and Quantity Limit Program Summary
Neprilysin Inhibitor (Entresto ) Prior Authorization and Quantity Limit Program Summary FDA APPROVED INDICATIONS DOSAGE 1 Indication Entresto Reduce the risk of cardiovascular (sacubitril/valsartan) death
More informationSASKATCHEWAN FORMULARY BULLETIN Update to the 60th Edition of the Saskatchewan Formulary
Saskatchewan Ministry of Health November 1, 2010 Drug Plan and Extended Benefits Branch Bulletin #126 ISSN 1923-077X SASKATCHEWAN FORMULARY BULLETIN Update to the 60th Edition of the Saskatchewan Formulary
More informationSASKATCHEWAN FORMULARY COMMITTEE BULLETIN TO THE 58th EDITION OF THE SASKATCHEWAN FORMULARY
Saskatchewan Ministry of Health Drug Plan and Extended Benefits Branch July 2008 Bulletin #115 ISSN 0708-3246 SASKATCHEWAN FORMULARY COMMITTEE BULLETIN TO THE 58th EDITION OF THE SASKATCHEWAN FORMULARY
More informationUPDATE AF Ontario Drug Benefit Formulary/Comparative Drug Index No. 41 Effective March 26, 2012 SUMMARY OF CHANGES
UPDATE AF Ontario Drug Benefit Formulary/Comparative Drug Index No. 41 Effective March 26, 2012 SUMMARY OF CHANGES TABLE OF CONTENTS Page New Multi-Source Drug(s) 2 Off Formulary Interchangeable Product(s)
More informationOntario Drug Benefit Formulary/ Comparative Drug Index
Ontario Drug Benefit Formulary/ Comparative Drug Index Edition 42 Summary of Changes December 2013 Effective January 03, 2014 Ministry of Health and Long-Term Care Table of Contents Additions to Formulary...
More informationSASKATCHEWAN FORMULARY COMMITTEE UPDATE BULLETIN TO THE 55th EDITION OF THE SASKATCHEWAN FORMULARY
Saskatchewan Health Drug Plan and Extended Benefits Branch April 2006 Bulletin #106 ISSN 0708-3246 SASKATCHEWAN FORMULARY COMMITTEE UPDATE BULLETIN TO THE 55th EDITION OF THE SASKATCHEWAN FORMULARY All
More informationUPDATE AX Ontario Drug Benefit Formulary/Comparative Drug Index No. 41 Effective August 29, 2013 SUMMARY OF CHANGES
UPDATE AX Ontario Drug Benefit Formulary/Comparative Drug Index No. 41 Effective August 29, 2013 SUMMARY OF CHANGES TABLE OF CONTENTS Page New Single Source Drug(s) 2 New Multi-Source Drug(s) 4 Off Formulary
More informationPublished by the Pharmaceutical Services Division to provide information for British Columbia s health care providers
Published by the Pharmaceutical Services Division to provide information for British Columbia s health care providers QuickLinks Keeping the Lines Clear... 1 Newsletter Notification Service... 1 Special
More informationOntario Drug Benefit Formulary/Comparative Drug Index
Ministry of Health and Long-Term Care Ontario Drug Benefit Formulary/Comparative Drug Index Edition 43 Summary of Changes April 2018 Effective April 30, 2018 Drug Programs Policy and Strategy Branch Ontario
More informationENTRESTO (sacubitril and valsartan) oral tablet
ENTRESTO (sacubitril and valsartan) oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This
More informationFamily Health, Nottingham Children s Hospital Date of submission February 2018
Nusinersen Title of Guideline Guideline for the prescribing and administration of Nusinersen to patients with Spinal Muscular Atrophy Type 1 Contact Name and Job Title (author) Dr Gabriel Chow- Consultant
More informationNB Drug Plans Formulary Update
Bulletin #915 October 30, 2015 NB Drug Formulary Update Please find attached a list of generic drug product updates for the New Brunswick Drug Formulary. Generic drug product additions New generic products
More informationUPDATE AB Ontario Drug Benefit Formulary/Comparative Drug Index No. 41 Effective October 25, 2011 SUMMARY OF CHANGES
UPDATE AB Ontario Drug Benefit Formulary/Comparative Drug Index No. 41 Effective October 25, 2011 SUMMARY OF CHANGES TABLE OF CONTENTS Page New Single Source Drug(s) 2 New Multi-Source Drug(s) 5 Off Formulary
More informationThe ACC Heart Failure Guidelines
The ACC Heart Failure Guidelines Fakhr Alayoubi, Msc,R Ph President of SCCP Cardiology Clinical Pharmacist Assistant Professor At King Saud University King Khalid University Hospital Riyadh-KSA 2017 ACC/AHA/HFSA
More informationBULLETIN # 74. Manitoba Drug Benefits and Interchangeability Formulary Amendments. The following amendments will take effect on October 17, 2013
BULLETIN # 74 Manitoba Drug Benefits and Interchangeability Formulary Amendments The following amendments will take effect on October 17, 2013 The amended Manitoba Specified Drug Regulation and Drug Interchangeability
More informationNB Drug Plans Formulary Update
Bulletin # 967 February 12, 2018 NB Drug Plans Formulary Update This update to the New Brunswick Drug Plans Formulary is effective February 12, 2018. Included in this bulletin: Regular Benefit Additions
More informationOntario Drug Benefit Formulary/Comparative Drug Index
Ontario Drug Benefit Formulary/Comparative Drug Index Edition 42 Summary of Changes - December 2014 Effective December 18, 2014 Ministry of Health and Long-Term Care Table of Contents New Multi-Source
More informationVELTASSA (patiromer) oral suspension
VELTASSA (patiromer) oral suspension Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy
More information1/4/18. Heart Failure Guideline Review and Update. Disclosure. Pharmacist Objectives. Pharmacy Technician Objectives. What is Heart Failure?
Disclosure Heart Failure Guideline Review and Update I have had no financial relationship over the past 12 months with any commercial sponsor with a vested interest in this presentation. Natalie Beiter,
More informationLEVEMIR (insulin detemir) subcutaneous solution LEVEMIR FLEXTOUCH (insulin detemir) subcutaneous solution pen-injector
LEVEMIR FLEXTOUCH (insulin detemir) subcutaneous solution pen-injector Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific
More information*NOTE: When submitting CPT code and 99239, it is recommended the measure be submitted each time the code is submitted for hospital discharge.
Quality ID #5 (NQF 0081): Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD) National Quality
More informationSABRIL (vigabatrin) powder for oral solution and oral tablet Vigadrone (vigabatrin) powder for oral solution Vigabatrin powder for oral solution
Vigabatrin powder for oral solution Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy
More informationPharmacy Medical Necessity Guidelines: Anticonvulsants/Mood Stabilizers
Pharmacy Medical Necessity Guidelines: Anticonvulsants/Mood Stabilizers Effective: December 18, 2017 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review
More informationCigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Nusinersen Table of Contents Coverage Policy... 1 General Background... 2 Coding/Billing Information... 5 References... 5 Effective Date... 10/15/2017 Next
More informationManagement of chronic heart failure: pharmacology. Giuseppe M.C. Rosano, MD, PhD, FHFA
Management of chronic heart failure: pharmacology. Giuseppe M.C. Rosano, MD, PhD, FHFA Declaration of potential conflict of interests Type of job or financial support Salary Ordinary funds Position in
More informationNB Drug Plans Formulary Update
Bulletin #980 August 23, 2018 NB Drug Plans Formulary Update This update to the New Brunswick Drug Plans Formulary is effective August 23, 2018. Included in this bulletin: Regular Benefit Additions Special
More informationUPDATE AZ Ontario Drug Benefit Formulary/Comparative Drug Index No. 41 Effective October 31, 2013 SUMMARY OF CHANGES
UPDATE AZ Ontario Drug Benefit Formulary/Comparative Drug Index No. 41 Effective October 31, 2013 SUMMARY OF CHANGES TABLE OF CONTENTS Page New Single Source Drug(s) 2 New Multi-Source Drug(s) 5 Off Formulary
More informationOntario Drug Benefit Formulary/Comparative Drug Index
Ontario Drug Benefit Formulary/Comparative Drug Index Edition 42 Summary of Changes - February 2015 Effective February 26, 2015 Ministry of Health and Long-Term Care Table of Contents New Multi-Source
More information